Skip to content

Acne Treatment With Active Oplon's Patches - 15-18 Years Old

Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01260766
Enrollment
50
Registered
2010-12-15
Start date
2011-01-31
Completion date
2011-06-30
Last updated
2010-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.

Detailed description

Patients with Acne Vulgaris were treated overnight with active patches. Effect is observed at the end of the treatment and 24 hours later.

Interventions

Patches are placed over acne lesion overnight. Treatment is a single treatment.

DEVICEPlacebo Patch

same as active patch

Sponsors

Oplon-Pure Science Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Acne Vulgaris * Over 15 years * Signing informed consent

Exclusion criteria

* Active treatment of acne * Change in hormonal therapy * Antibiotic treatment in a week prior to the experiment * Sensitive skin * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Severity Score of lesionSeverity Score of lesion [Time Frame: 24 hours following patch removal]Lesions were ranked by investigator according to severity whereas: 0-clear, 1-mild, 2-moderate, 3-sever

Secondary

MeasureTime frameDescription
Severity Score of lesionSeverity Score of lesion [Time Frame: 12 hours with the patch]Lesions were ranked by investigator according to severity whereas: 0-clear, 1-mild, 2-moderate, 3-sever

Countries

Israel

Contacts

Primary ContactAvner Shemer, M.D.
ashemer1@gmail.com: +972-524575677

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026